Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00847535 · ClinicalTrials.gov registry record · Phase 2
An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells as Therapy for Stress Urinary Incontinence
A Phase 2 study of Stress Urinary Incontinence and Cell Therapy, sponsored by Cook MyoSite.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 3
- Study locations
NCT00847535 is a Phase 2 study of Stress Urinary Incontinence and Cell Therapy that has completed, run by Cook MyoSite. The registered enrollment target is 66 participants, below the 161-participant average among 35 other Stress Urinary Incontinence trials with a reported enrollment target (59% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00847535, a Phase 2 study of Stress Urinary Incontinence and Cell Therapy, has completed, sponsored by Cook MyoSite.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a clinical investigation approved by US FDA and Canadian Health Authority to study the safety and potential effectiveness of the autologous muscle cells for the treatment of stress urinary incontinence.
Conditions Studied
Interventions
- BIOLOGICAL autologous muscle cell injection
Study Locations (3)
Michigan
- Wm Beaumont Hospital - Royal Oak
Tennessee
- Vanderbilt University Medical Center - Nashville
Ontario
- Sunnybrook Health Sciences Center - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2008-10-09 |
| Est. Completion | 2011-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00847535
The ClinicalTrials.gov registry entry for NCT00847535 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 161-participant average among 35 other Stress Urinary Incontinence trials with a reported enrollment target (59% lower). The listed sponsor is Cook MyoSite, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stress Urinary Incontinence appearing as the primary indexed condition, and to 1 intervention - of which autologous muscle cell injection is the first listed.
NCT00847535 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Michigan, Tennessee, Ontario.
Frequently Asked Questions
What is clinical trial NCT00847535 about?
NCT00847535 is a clinical study titled "An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells as Therapy for Stress Urinary Incontinence". This is a clinical investigation approved by US FDA and Canadian Health Authority to study the safety and potential effectiveness of the autologous muscle cells for the treatment of stress urinary incontinence.
What is the current status of trial NCT00847535?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2008-10-09. Estimated completion is 2011-11-02.
What conditions does trial NCT00847535 study?
This clinical trial studies the following conditions: Stress Urinary Incontinence, Cell Therapy.
What interventions are being tested in trial NCT00847535?
The interventions under investigation include: autologous muscle cell injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT00847535?
This trial is sponsored by Cook MyoSite, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00847535 being conducted?
This trial has 3 study locations across Michigan, Tennessee, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stress Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
RECRUITING · Phase 2
-
The Anabolic Effect of Testosterone on Pelvic Floor Muscles
RECRUITING · Phase 2
-
Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence
COMPLETED · Phase 2
-
ProACT Post-Approval Study
RECRUITING · NA
-
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
RECRUITING · NA
-
Comparison of Virtual Pelvic Floor Physical Therapy With a Pelvic Floor Trainer in the Treatment of Stress Urinary Incontinence.
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.